All You Need to Know About Semaglutide
Semaglutide is a once-weekly GLP-1 receptor agonist best known as the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). This guide covers how it works, what the STEP and SUSTAIN trials actually found, how it's dosed, its side effects, and who it suits. [1]
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and supports blood sugar control — producing clinically meaningful weight loss when combined with lifestyle changes.
In the STEP 1 trial, semaglutide 2.4 mg weekly produced ~14.9% average weight loss at 68 weeks versus 2.4% on placebo, and 86.4% of participants lost at least 5% of body weight. [1]
Benefits extend beyond weight. In SUSTAIN-6, semaglutide cut major adverse cardiovascular events by 26% in people with type 2 diabetes at high cardiovascular risk. [3]
Safe use requires medical supervision — screening, gradual dose escalation over 16 weeks, and awareness of who should avoid or use caution with semaglutide.
Wondering if medically supervised semaglutide is right for you?
Check Your Eligibility →Introduction
Many people first hear about semaglutide as the active ingredient in Ozempic, a medicine approved for type 2 diabetes. But a growing body of high-quality clinical evidence shows semaglutide is also highly effective for medical weight management — and a higher-dose product, Wegovy, is specifically approved for chronic weight loss in eligible adults.
For people who have struggled with their weight for years, semaglutide can deliver results that lifestyle changes alone often cannot — and those results may meaningfully improve long-term metabolic health when paired with sustainable nutrition and activity habits. This guide explains what the products are, how semaglutide works in the body, what the clinical trials actually found, how it is dosed, who it suits, and what to expect at each stage.
Semaglutide is a once-weekly injectable GLP-1 receptor agonist. Sold as Wegovy for weight management and Ozempic for type 2 diabetes, it works by mimicking a natural gut hormone that regulates hunger and blood sugar. It is a prescription medicine that should always be used under clinical supervision alongside diet and exercise.
Wegovy vs Ozempic: What Are They?
Wegovy is a once-weekly injection containing semaglutide, intended for chronic weight management alongside lifestyle intervention. Ozempic is also a once-weekly semaglutide injection, but its primary approved use is improving blood sugar control in adults with type 2 diabetes — with weight loss occurring as a secondary effect. Both belong to a class of medicines called GLP-1 receptor agonists.
The most important practical difference is the maintenance dose: Wegovy is titrated to a higher dose (2.4 mg) developed specifically for obesity, while Ozempic's approved maintenance doses are lower. This is a key reason average weight loss tends to be greater with Wegovy. [1]
Quick Comparison
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Medicine class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Primary approved use | Chronic weight management | Type 2 diabetes |
| Administration | Once-weekly injection | Once-weekly injection |
| Maintenance dose | 2.4 mg | 0.5–2 mg |
| Weight loss | Primary goal | Secondary effect |
Suitability is individual. Which product is appropriate depends on your health profile, treatment goals, and prescriber assessment.
How Semaglutide Works
Semaglutide mimics a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), which the gut releases in response to eating. GLP-1 helps regulate appetite and blood sugar by acting on the brain, pancreas, and digestive system. [2]
In practical terms, semaglutide works through three complementary mechanisms:
- →Appetite regulation: acts on brain centres that control hunger, helping you feel satisfied with less food and reducing cravings.
- →Slowed gastric emptying: food leaves the stomach more slowly, prolonging fullness after meals and steadying post-meal blood sugar.
- →Glucose-dependent insulin release: prompts the pancreas to release insulin when blood sugar rises, supporting glycaemic control without the same low-blood-sugar risk as some older medicines.
Because semaglutide targets the biological drivers of hunger — not willpower — it helps address one of the hardest parts of weight management: the appetite signals that make sustained calorie reduction so difficult through diet alone.
Can Semaglutide Be Used for Weight Loss?
Yes — and the evidence base is unusually strong. The landmark STEP 1 trial randomised 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg weekly or placebo, both alongside lifestyle intervention, for 68 weeks. The results were striking. [1]
Bars scaled to the semaglutide result. Source: Wilding et al., NEJM 2021 (STEP 1). [1]
Proportion of participants reaching each weight-loss threshold shows how consistently semaglutide outperformed placebo — not just on average, but across the group:
Source: STEP 1 trial, Wilding et al., NEJM 2021. [1]
Weight loss was sustained over the longer term. In the STEP 5 trial, semaglutide 2.4 mg produced 15.2% average weight loss at two years (104 weeks) versus 2.6% on placebo — showing the effect is durable when treatment continues alongside lifestyle support. [4]
Newer, higher-dose formulations under investigation have reported even larger reductions — around 20.7% average weight loss at 72 weeks in one trial update — but these reflect investigational dosing rather than the currently approved 2.4 mg regimen, and should be interpreted with that context. [5]
Beyond Weight: Blood Sugar and Heart Health
Semaglutide's benefits extend past the scale. It supports blood sugar control primarily through glucose-dependent effects — helping the pancreas release insulin when blood sugar rises — which improves long-term glycaemic control for many people with type 2 diabetes. By slowing gastric emptying, it also blunts sharp post-meal glucose spikes.
Cardiovascular Risk Reduction
In the SUSTAIN-6 trial, people with type 2 diabetes at high cardiovascular risk who took semaglutide had a 26% lower risk of major adverse cardiovascular events — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — compared with placebo over 104 weeks (hazard ratio 0.74). SUSTAIN-6 was primarily designed to confirm cardiovascular safety (non-inferiority); the reduction in events was a positive secondary finding rather than the trial's pre-specified goal, but it has been consistently reported across later analyses. [3]
Event rates over the trial period; 26% relative risk reduction (HR 0.74, 95% CI 0.58–0.95). Source: Marso et al., NEJM 2016 (SUSTAIN-6). [3]
These cardiovascular findings come from trials in people with type 2 diabetes and established cardiovascular risk. They do not automatically apply to every person taking semaglutide for weight loss, and cardiovascular benefit should be discussed individually with your clinician.
How Long Does Weight Loss Take?
Results vary from person to person. Some people notice reduced appetite within the first couple of weeks, while measurable weight loss typically builds over months as the dose is escalated. Weight loss is often nonlinear — progress comes in steps rather than a straight line — and consistency with medication, nutrition, movement, sleep, and follow-ups matters far more than short-term fluctuations on the scale.
We emphasise steady, sustainable weight loss under medical guidance rather than quick fixes that are hard to maintain. Structured coaching, tracking tools, and regular clinician check-ins help you stay consistent and safe.
How Semaglutide Is Dosed
Semaglutide is started low and increased gradually — a process called dose escalation — to let the body adjust and to reduce common gastrointestinal side effects. In STEP 1, dosing followed this schedule over the first 16 weeks: [1]
Wegovy is supplied in a pre-filled pen for subcutaneous injection, typically into the abdomen, thigh, or upper arm as instructed by a clinician. Used needles must be disposed of in an approved sharps container. Always follow the product instructions and your prescriber's dosing plan.
Gradual escalation is the single most effective way to reduce nausea and other gastrointestinal effects. If side effects limit an increase, your clinician can slow the schedule or hold at a lower dose — tolerability comes first.
Side Effects: What to Expect
The most common side effects are gastrointestinal and tend to appear during dose escalation. Most are mild to moderate and improve as the body adjusts. [1]
| Common effects | Less common — seek advice |
|---|---|
| Nausea | Persistent severe abdominal pain |
| Vomiting | Signs of pancreatitis |
| Diarrhoea | Gallbladder symptoms |
| Constipation | Allergic reaction |
| Reduced appetite | Changes in vision (in diabetes) |
This is not a complete list. Report anything unexpected or severe to your prescriber promptly.
Who Should Not Use Semaglutide?
Semaglutide may not be appropriate — or may require special precautions — for some people, which is why prescriber review is essential. It is generally avoided or used with caution in:
- →People with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- →Those who are pregnant, breastfeeding, or planning pregnancy.
- →People with significant gastrointestinal disease or a history of pancreatitis.
- →Anyone with a known allergy to semaglutide or product ingredients.
This isn't a complete list. A Karespot consultation includes a full medical history and medication review before therapy begins — safety and suitability always come first.
Other Weight-Loss Medications
Depending on your clinical profile and availability, other prescription options may be considered — all under healthcare-professional guidance:
| Medication | Class / type | Primary use |
|---|---|---|
| Oral semaglutide (Rybelsus) | GLP-1 receptor agonist (tablet) | Type 2 diabetes |
| Tirzepatide (Mounjaro) | GIP/GLP-1 receptor agonist | Diabetes & weight management |
| Liraglutide (Saxenda) | GLP-1 receptor agonist | Weight management |
| Dulaglutide (Trulicity) | GLP-1 receptor agonist | Type 2 diabetes |
| Metformin | Biguanide | Type 2 diabetes (modest weight effect) |
| Orlistat | Fat-absorption blocker | Weight management |
Suitability depends on individual assessment. Not all options are appropriate for everyone.
Before You Start Semaglutide
Read the package leaflet carefully for dosing, injection technique, storage, disposal, and side effects. Begin treatment only after consultation with a qualified prescriber experienced in medical weight management. During your consultation, your clinician should assess whether semaglutide is appropriate for you, then build a plan that includes monitoring, lifestyle support, and regular follow-ups.
Semaglutide is one of the most effective medical weight-management tools available today — but it works best as part of a supervised programme that combines the medication with nutrition, movement, and behavioural support. Medication opens the door; sustainable habits keep it open.
Semaglutide Availability in India
Medically supervised semaglutide treatment is available through Karespot across major cities in North and West India. Following semaglutide's patent expiry, generic and biosimilar formulations have improved accessibility for eligible patients.
Uttarakhand: Dehradun, Haridwar, Rishikesh, Nainital
Delhi NCR: Delhi, Noida, Gurgaon
Uttar Pradesh: Lucknow, Kanpur, Agra, Varanasi, Meerut
Maharashtra: Mumbai
Ready to explore medically supervised weight management?
Check Your Eligibility →Frequently Asked Questions
Is semaglutide the same as Ozempic and Wegovy?
How much weight can you lose on semaglutide?
How long does semaglutide take to work?
Does semaglutide have cardiovascular benefits?
What are the most common side effects of semaglutide?
Who should not take semaglutide?
Do I still need diet and exercise on semaglutide?
Is semaglutide available in India?
What happens if I stop taking semaglutide?
References
This article is based on peer-reviewed clinical trials, regulatory sources, and reputable medical publications. All statistics are drawn directly from the cited primary sources.
Dr. Prakrati Garg is a Research Associate and published researcher in Biotechnology at Shoolini University, and Content Strategist at Karespot. With deep expertise in herbal drug development, nanotechnology, and advanced drug delivery systems, she brings a rigorous scientific lens to health and wellness content. Her research background, including published work and patents in herbal-based formulations, informs her ability to translate complex medical and nutritional science into clear, evidence-based insights for readers.
Dr. Sana Umar is an Assistant Professor at Doon Medical College and Medical Reviewer at Karespot. A Clinical Pathologist with FRCP credentials and NMC registration (UKMC Reg. 8506), she ensures all clinical content aligns with current prescribing guidelines and evidence-based best practices in weight management and metabolic medicine.
